{"id":5650,"date":"2020-03-04T15:10:05","date_gmt":"2020-03-04T14:10:05","guid":{"rendered":"https:\/\/staybletherapeutics.com\/sv\/cision-feed\/stayble-har-godkants-for-notering-pa-nasdaq-first-north-growth-market-med-forsta-handelsdag-den-9-mars-2020\/"},"modified":"2020-03-04T15:10:05","modified_gmt":"2020-03-04T14:10:05","slug":"stayble-har-godkants-for-notering-pa-nasdaq-first-north-growth-market-med-forsta-handelsdag-den-9-mars-2020","status":"publish","type":"cision-feed","link":"https:\/\/staybletherapeutics.com\/sv\/cision-feed\/stayble-har-godkants-for-notering-pa-nasdaq-first-north-growth-market-med-forsta-handelsdag-den-9-mars-2020\/","title":{"rendered":"Stayble har godk\u00e4nts f\u00f6r notering p\u00e5 Nasdaq First North Growth Market med f\u00f6rsta handelsdag den 9 mars 2020"},"content":{"rendered":"<p style=\"margin-bottom:8px\"><span style=\"font-family:tahoma,arial,helvetica,sans-serif\"><span style=\"font-size:10pt\"><span style=\"line-height:115%\"><span style=\"color:#3b3838\">Den 21 februari kommunicerade Stayble att Bolagets unitemission om 35 MSEK tecknades till totalt cirka 153 MSEK (vilket motsvarar en teckningsgrad om totalt cirka 436 %). Bolaget tillf\u00f6rs genom emissionen omkring 830 nya aktie\u00e4gare och totalt emitteras 2&nbsp;850 000&nbsp;aktier samt 2&nbsp;850&nbsp;000 teckningsoptioner av serie TO1. Teckningsoptionerna kan tillf\u00f6ra Bolaget ytterligare 35 till 70 MSEK f\u00f6re emissionskostnader i december 2020. Fullst\u00e4ndiga villkor f\u00f6r teckningsoptionerna av serie TO1 finns i det prospekt som offentliggjordes den 31 januari 2020. <\/span><\/span><\/span><\/span><\/p>\n<p><span style=\"font-family:tahoma,arial,helvetica,sans-serif\"><span style=\"font-size:10pt\"><span style=\"line-height:115%\"><span style=\"color:#3b3838\">Kortnamnet f\u00f6r Bolagets aktier p\u00e5&nbsp;Nasdaq First North \u00e4r STABL.<\/span><\/span><\/span><\/span><\/p>\n<p><span style=\"font-family:tahoma,arial,helvetica,sans-serif\"><span style=\"font-size:10pt\"><span style=\"line-height:115%\"><span style=\"color:#3b3838\">Kortnamnet f\u00f6r teckningsoptionerna av serie TO1 p\u00e5&nbsp;Nasdaq First North \u00e4r STABL TO1.<\/span><\/span><\/span><\/span><\/p>\n<p><strong><span style=\"font-size:10pt\"><span style=\"font-family:arial,helvetica,sans-serif\">R\u00e5dgivare<\/span><\/span><\/strong><br \/>\n<span style=\"font-size:10pt\"><span style=\"line-height:115%\"><span style=\"color:#3b3838\"><span style=\"font-family:arial,helvetica,sans-serif\">Mangold \u00e4r finansiell r\u00e5dgivare och Advokatfirman Schj\u00f8dt \u00e4r legal r\u00e5dgivare.<\/span><\/span><\/span><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nasdaq Stockholm AB har idag godk\u00e4nt Stayble Therapeutics AB:s (\u201dStayble\u201d eller \u201dBolaget\u201d) ans\u00f6kan om upptagande till handel av Bolagets aktier och teckningsoptioner av serie TO1 p\u00e5 Nasdaq First North Growth Market (\u201dNasdaq First North\u201d). F\u00f6rsta dag f\u00f6r handel p\u00e5 Nasdaq First North \u00e4r fastst\u00e4lld till den 9 mars 2020.<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed\/5650"}],"collection":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed"}],"about":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/types\/cision-feed"}],"replies":[{"embeddable":true,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/comments?post=5650"}],"version-history":[{"count":0,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed\/5650\/revisions"}],"wp:attachment":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/media?parent=5650"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}